Home Tags Celldex Therapeutics

Tag: Celldex Therapeutics

Glembatumumab Vedotin Does Not Meet Primary Endpoint in METRIC Study

The randomized, Phase IIb METRIC Study of glembatumumab vedotin, also known as CDX-011, an antibody-drug conjugate or ADC being developed by Celldex, compared to...

Market Trend: Cancer Immunotherapy Destined for Growth

According to data provided by Allied Market Research, the global cancer immunotherapy market is expected to grow to $117.14 billion by 2022, growing at...

Celldex Therapeutics Acquires Kolltan Pharmaceuticals – Expands Antibody and Immuno-Oncology Portfolio

Celldex Therapeutics has entered into a definitive agreement to acquire Kolltan Pharmaceuticals, a clinical-stage company focused on the discovery and development of novel, antibody-based drugs...
Featured Image: Nyhavn, Copenhagen, Denmark. Courtesy: © Fotolia. Used with permission.

Glembatumumab vedotin Shows Encouraging anti-tumor Activity Checkpoint Inhibitor-refractory Metastatic Melanoma

Results from a phase II trial presented in a poster at the annual meeting of the European Society of Medical Oncology, held in Copenhagen,...

FEATURED RESOURCES